Atossa Therapeutics Management
Management criteria checks 3/4
Atossa Therapeutics' CEO is Steve Quay, appointed in Apr 2009, has a tenure of 15.08 years. total yearly compensation is $2.36M, comprised of 30% salary and 70% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth $4.01K. The average tenure of the management team and the board of directors is 3.3 years and 12.3 years respectively.
Key information
Steve Quay
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 30.0% |
| CEO tenure | 15.1yrs |
| CEO ownership | 0.002% |
| Management average tenure | 3.3yrs |
| Board average tenure | 12.3yrs |
Recent management updates
Recent updates
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Mar 07
We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Nov 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
Apr 26We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Jan 09Atossa Therapeutics: Still Gets An 'Incomplete' Rating
Oct 11We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
Sep 25Atossa Therapeutics GAAP EPS of -$0.05
Aug 08Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth
May 12A First Assessment On Atossa Therapeutics
Dec 10We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 02Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Sep 22Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Jul 17Atossa Therapeutics: Hope Springs Eternal
Jun 30Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Jun 16Atossa reaches a two-year high ahead of data readout for breast cancer therapy
Jun 07Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Apr 02Atossa updates on single-patient study for Endoxifen
Feb 04Atossa halts Endoxifen breast cancer study after positive data
Feb 02Atossa Therapeutics prices ~$25M direct offering, stock -23% PM
Jan 06Atossa Therapeutics prices $14M registered direct offering
Dec 17We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate
Dec 10
Atossa Therapeutics plummets 38% after it raises $20M in public offering
Dec 09Atossa Therapeutics EPS in-line
Nov 13Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%
Nov 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$706k | -US$30m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$3m | US$706k | -US$27m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$21m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$6m | US$659k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$28m |
| Jun 30 2021 | n/a | n/a | -US$26m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$3m | US$601k | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$13m |
| Jun 30 2020 | n/a | n/a | -US$13m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$6m | US$601k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$25m |
| Dec 31 2018 | US$2m | US$582k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$22m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$1m | US$520k | -US$11m |
Compensation vs Market: Steve's total compensation ($USD2.36M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Quay (72 yo)
15.1yrs
Tenure
US$2,356,220
Compensation
Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.1yrs | US$2.36m | 0.0021% $ 4.0k | |
| Senior VP of Finance & Principal Accounting Officer | 3.3yrs | US$687.46k | 0% $ 0 | |
| Senior Vice President of Administration & HR | 9.8yrs | no data | no data | |
| Vice President of Investor & Public Relations | 2.3yrs | no data | no data | |
| Interim Chief Medical Officer | 1.6yrs | no data | no data |
3.3yrs
Average Tenure
Experienced Management: ATOS's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.1yrs | US$2.36m | 0.0021% $ 4.0k | |
| Independent Director | 10.2yrs | US$146.17k | 0% $ 0 | |
| Independent Director | 12.3yrs | US$144.92k | 0.00021% $ 397.3 | |
| Director | 15.1yrs | US$116.17k | 0% $ 0 | |
| Independent Director | 12.8yrs | US$144.92k | 0.000080% $ 151.4 | |
| Independent Director | less than a year | US$93.98k | 0.020% $ 37.7k | |
| Independent Director | less than a year | no data | no data |
12.3yrs
Average Tenure
66yo
Average Age
Experienced Board: ATOS's board of directors are seasoned and experienced ( 12.3 years average tenure).